| P50 | author | Sherene Loi | Q42315566 |
| | Evandro de Azambuja | Q38293745 |
| P2093 | author name string | Kamal S Saini | |
| | Christos Sotiriou | |
| | Martine Piccart | |
| | Otto Metzger-Filho | |
| | Hatem A Azim | |
| P2860 | cites work | A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor | Q24648517 |
| | Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab | Q27640593 |
| | Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 |
| | PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. | Q27824819 |
| | Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells | Q27824846 |
| | Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer | Q27824847 |
| | PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer | Q27824857 |
| | Lapatinib plus capecitabine for HER2-positive advanced breast cancer | Q27851403 |
| | Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer | Q27851549 |
| | Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer | Q27851553 |
| | PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. | Q27851582 |
| | Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 |
| | Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets | Q28140238 |
| | Targeting the phosphoinositide 3-kinase pathway in cancer | Q29615809 |
| | Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 |
| | The role of mitogen-activated protein (MAP) kinase in breast cancer | Q30308930 |
| | Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative me | Q30376023 |
| | Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. | Q40144433 |
| | Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers | Q40321985 |
| | Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells | Q40321992 |
| | Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1. | Q40335378 |
| | Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells | Q40344963 |
| | The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. | Q40571024 |
| | A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors | Q40631570 |
| | Requirement for neuregulin receptor erbB2 in neural and cardiac development | Q41269625 |
| | Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer | Q42435519 |
| | Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome | Q42468745 |
| | Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors | Q42948964 |
| | Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study | Q43121691 |
| | Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall | Q43180234 |
| | Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer | Q43270036 |
| | Expression of cellular oncogenes in human malignancies | Q43491818 |
| | Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth | Q44120544 |
| | Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies | Q45246419 |
| | A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors | Q46076293 |
| | Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer | Q46116627 |
| | Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. | Q46966638 |
| | Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy | Q47587986 |
| | The PIK3CA gene is mutated with high frequency in human breast cancers. | Q53366750 |
| | Neoadjuvant anthracycline and trastuzumab for breast cancer: is concurrent treatment safe? | Q54609789 |
| | Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. | Q54668841 |
| | Sequential or Concurrent Administration of Trastuzumab in Early Breast Cancer? Too Early to Judge | Q57578945 |
| | Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2 | Q62604209 |
| | Trastuzumab in the treatment of breast cancer | Q81374982 |
| | Whither HER2-related therapeutics? | Q82743585 |
| | Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM | Q84592604 |
| | Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized | Q31089499 |
| | Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study | Q33377626 |
| | Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy | Q33393360 |
| | The multiple roles of PTEN in tumor suppression | Q33849727 |
| | A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer | Q34077853 |
| | Neoadjuvant trastuzumab induces apoptosis in primary breast cancers | Q34394358 |
| | Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer | Q34496969 |
| | Resiliency and vulnerability in the HER2-HER3 tumorigenic driver | Q34551761 |
| | Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers | Q34679149 |
| | Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer | Q34775370 |
| | erbB2 is required for G protein-coupled receptor signaling in the heart | Q35127519 |
| | Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers | Q35566231 |
| | Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor. | Q35625995 |
| | Essential roles of Her2/erbB2 in cardiac development and function | Q35641803 |
| | Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells | Q35973421 |
| | Resistance to Trastuzumab in Breast Cancer. | Q36318226 |
| | Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea | Q36875372 |
| | Lapatinib-associated toxicity and practical management recommendations | Q36900690 |
| | Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain | Q36954809 |
| | Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer | Q37117151 |
| | Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy | Q37163797 |
| | Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry | Q37205563 |
| | Targeting Her-2/neu in breast cancer: as easy as this! | Q37245691 |
| | Jumping higher: is it still possible? The ALTTO trial challenge | Q37338235 |
| | Cardiac toxicity with anti-HER-2 therapies: what have we learned so far? | Q37471532 |
| | Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. | Q37523202 |
| | Trastuzumab versus lapatinib: the cardiac side of the story | Q37565843 |
| | Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer | Q37626334 |
| | Simultaneous targeting of estrogen receptor and HER2 in breast cancer | Q37782093 |
| | Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells | Q39677802 |
| | In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. | Q39830937 |
| P921 | main subject | trastuzumab | Q412616 |
| P304 | page(s) | S20-7 | |
| P577 | publication date | 2011-10-01 | |
| P1433 | published in | The Breast | Q7719928 |
| P1476 | title | Beyond trastuzumab: new treatment options for HER2-positive breast cancer | |
| P478 | volume | 20 Suppl 3 | |